Skip to main content

Advertisement

SpringerLink
Log in

Usefulness of 131I-SPECT/CT and 18F-FDG PET/CT in Evaluating Successful 131I and Retinoic Acid Combined Therapy in a Patient with Metastatic Struma Ovarii

  • Case Report
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Metastatic struma ovarii is an extremely rare disease, and the treatment of choice has not been established. Here, we introduce the case of a 36-year-old female pregnant patient with metastatic struma ovarii. Initial treatment was an exploratory laparotomy to remove multiple peritoneal masses. After delivery, a total thyroidectomy was done for the further 131I-therapy. 131I-SPECT/CT and 18 F-FDG PET/CT showed multiple hepatic metastases and extensive peritoneal seeding nodules. Multiple 131I and retinoic acid combination therapies were performed, resulting in marked improvement. 131I-SPECT/CT and 18 F-FDG PET/CT were quite useful for evaluating the biologic characteristics of the metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. DeSimone CP, Lele SM, Modesitt SC. Malignant struma ovarii: a case report and analysis of cases reported in the literature with focus on survival and I131 therapy. Gynecol Oncol. 2003;89(3):543–8.

    Article  PubMed  Google Scholar 

  2. Shrimali RK, Shaikh G, Reed NS. Malignant struma ovarii: the west of Scotland experience and review of literature with focus on postoperative management. J Med Imaging Radiat Oncol. 2012;56(4):478–82. doi:10.1111/j.1754-9485.2012.02394.x.

    Article  PubMed  Google Scholar 

  3. Navarro MD, Tan MA, Lovecchio JL, Hajdu SI. Case report: malignant struma ovarii. Ann Clin Lab Sci. 2004;34(1):107–12.

    PubMed  Google Scholar 

  4. Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab. 2008;22(6):989–1007. doi:10.1016/j.beem.2008.09.013.

    Article  CAS  PubMed  Google Scholar 

  5. Oh S, S-h M, Park D, Cho B, Jung K, Lee D, et al. Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(10):1798–805. doi:10.1007/s00259-011-1849-2.

    Article  CAS  PubMed  Google Scholar 

  6. Paeng JC, Kang KW, do Park J, Oh SW, Chung JK. Alternative medical treatment for radioiodine-refractory thyroid cancers. Nucl Med Mol Imaging. 2011;45(4):241–7. doi:10.1007/s13139-011-0107-7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am J Roentgenol. 2008;191(6):1785–94. doi:10.2214/ajr.08.1218.

    Article  PubMed  Google Scholar 

  8. Xue YL, Qiu ZL, Song HJ, Luo QY. Value of (1)(3)(1)I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature. Eur J Nucl Med Mol Imaging. 2013;40(5):768–78. doi:10.1007/s00259-012-2310-x.

    Article  CAS  PubMed  Google Scholar 

  9. Zakhem A, Aftimos G, Kreidy R, Salem P. Malignant struma ovarii: report of two cases and selected review of the literature. J Surg Oncol. 1990;43(1):61–5.

    Article  CAS  PubMed  Google Scholar 

  10. Checrallah A, Medlej R, Saade C, Khayat G, Halaby G. Malignant struma ovarii: an unusual presentation. Thyroid Off J AmThyroid Assoc. 2001;11(9):889–92. doi:10.1089/105072501316973163.

    Article  CAS  Google Scholar 

  11. Steinman RA, De Castro IO, Shrayyef M, Chengazi V, Giampoli E, Van Der Sloot P, et al. Two cases of malignant struma ovarii with metastasis to pelvic bone. Gynecol Obstet Investig. 2013;75(2):139–44. doi:10.1159/000345863.

    Article  Google Scholar 

  12. Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC, et al. Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2009;28(5):405–22. doi:10.1097/PGP.0b013e3181a27777.

    Article  Google Scholar 

  13. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endoc Eur Fed Endoc Soc. 2005;153(5):651–9. doi:10.1530/eje.1.02014.

    Article  CAS  Google Scholar 

  14. Willemse PHB, Oosterhuis JW, Aalders JG, Piers DA, Sleijfer DT, Vermey A, et al. Malignant struma ovarii treated by ovariectomy, thyroidectomy, and 131I administration. Cancer. 1987;60(2):178–82. doi:10.1002/1097-0142(19870715)60:2<178::AID-CNCR2820600210>3.0.CO;2-Q.

    Article  CAS  PubMed  Google Scholar 

  15. Janszen EW, van Doorn HC, Ewing PC, de Krijger RR, de Wilt JH, Kam BL, et al. Malignant struma ovarii: good response after thyroidectomy and I ablation therapy. Clinic Med Oncol. 2008;2:147–52.

    Google Scholar 

Download references

Conflict of Interest

Hyo Jung Seo, Young Hoon Ryu, Inki Lee, Hye Sook Min, Keon Wook Kang, Dong Soo Lee, Dae-hee Lee and June-Key Chung declare that they have no conflict of interest.

Ethical Standard

The patient gave informed consent prior to inclusion in the study.

Author information

Authors and Affiliations

  1. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul, Korea

    Hyo Jung Seo & Dong Soo Lee

  2. Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehangno, Jongro-gu, Seoul, 110-744, Korea

    Hyo Jung Seo, Inki Lee, Keon Wook Kang, Dong Soo Lee & June-Key Chung

  3. Department of Nuclear Medicine, Anyang SAM Hospital, Gyeonggi-do, Korea

    Hyo Jung Seo

  4. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea

    Young Hoon Ryu

  5. Department of Pathology, Seoul National University Hospital, Seoul, Korea

    Hye Sook Min

  6. Departiment of Oncology, GSAM Hosptial, Gyeonggi-do, Korea

    Dae-hee Lee

Authors
  1. Hyo Jung Seo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Young Hoon Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Inki Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hye Sook Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keon Wook Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dong Soo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dae-hee Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. June-Key Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to June-Key Chung.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seo, H.J., Ryu, Y.H., Lee, I. et al. Usefulness of 131I-SPECT/CT and 18F-FDG PET/CT in Evaluating Successful 131I and Retinoic Acid Combined Therapy in a Patient with Metastatic Struma Ovarii. Nucl Med Mol Imaging 49, 52–56 (2015). https://doi.org/10.1007/s13139-014-0295-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-014-0295-z

Keywords

Search

Navigation